Silexion Therapeutics: Shareholders Reject Capital Increase and Reverse Split

What Happened

• Silexion Therapeutics filed an 8-K on Sept. 25, 2026 reporting results from a reconvened extraordinary general meeting held Sept. 23, 2026. Holders of 2,208,353 ordinary shares (about 36.8% of issued and outstanding shares) were present in person or by proxy. Under Article 21.3 of the company’s articles, after a half-hour lapse the shareholders present constituted a quorum and the meeting proceeded.
• Shareholders voted on two proposals: (1) an increase to authorized share capital by 175,000,000 ordinary shares (from US$2,146,500 / 15,900,000 shares to US$25,771,500 / 190,900,000 shares); and (2) authorization for the Board to effect a 1-for-15 reverse share split of all issued, outstanding and authorized but unissued ordinary shares. Neither proposal received a simple majority of votes of shareholders present and therefore failed.

Key Details

• Shares represented at meeting: 2,208,353 ordinary shares (~36.8% of issued and outstanding).
• Authorized share capital increase proposed: add 175,000,000 ordinary shares (proposed new total 190,900,000 shares; par value US$0.135).
• Vote on Authorized Share Capital Increase (excluding abstentions): For 536,203 (24.6%); Against 1,645,147 (75.4%); Abstentions 27,003.
• Vote on Reverse Share Split (excluding abstentions): For 571,411 (25.9%); Against 1,636,939 (74.1%); Abstentions 3.

Why It Matters

• Because both proposals failed, the company’s authorized share capital and the number of outstanding shares remain unchanged and the Board is not authorized to implement the proposed 1-for-15 reverse split.
• For investors, that means no immediate change to share count, par value or share consolidation resulting from these proposals; any future effort to change authorized capital or effect a reverse split would require new shareholder approval.
• The turnout and decisive vote margins signal shareholder resistance to these specific capital-structure changes as presented.